Rene Haas, CEO of ARM Holdings, believes the biggest potential for artificial intelligence lies in healthcare. “Designing a chip versus curing cancer—I’m going to bet that the killer app for AI is in health,” he said, pointing to areas such as drug research, gene studies, genomics, and clinical trials.
Haas noted that AI can significantly accelerate the lengthy clinical trial process and drive innovation in drug discovery, helping combat diseases like cancer and Alzheimer’s.
Since the announcement of ARM’s Stargate AI technology in January, demand for the platform has only grown. Haas emphasised that there is “no scaling back” from ARM’s side and that Stargate activities show no signs of slowing down.
Under his leadership, ARM has doubled its headcount, reflecting the company’s commitment to scaling operations and strengthening its research and development capabilities.
Haas also highlighted the strategic importance of regional talent, noting that developing intellectual property and subsystems relies on the unique skills found in specific locations.
Semiconductors, he said, have become critical for every country, with India focusing on building an indigenous design and development ecosystem. ARM has been actively involved in this space, and Haas sees significant growth opportunities ahead in India.
“Semiconductors are so strategic, and the talent in this region is essential for what we do,” Haas added, underlining ARM’s long-term commitment to innovation and expansion in both AI technology and healthcare applications.
(Edited by : Ajay Vaishnav)